You just read:

INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease

News provided by

Janssen Pharmaceutical Companies

Nov 03, 2017, 10:30 ET